TWi's ANDA of Bupropion HCI ER Tablet has been approved by US FDA

November 7, 2017. TWi Pharmaceuticals, Inc. (“TWi”) (Stock Ticker: 4180.TT) today announced that its ANDA (“Abbreviated New Drug Application”) of Bupropion HCl ER Tablets (TWi-015) has been officially approved by US FDA. The Company will start the preparation for launch in the US market accordingly.

Bupropion HCl ER Tablets is indicated for depressive disorder. According to IMS Health data, the total sales of Bupropion HCl ER Tablets in the US were approximately US$760 million for the 12 months ended August 2017.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com

Contact :
Angela Luan
Investor Relations
Email: angela.luan@twipharma.com